Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 35 entries
Sorted by: Best Match Show Resources per page
Apnea with ketamine sedation in a patient with severe anorexia nervosa: A case report.

Eating and weight disorders : EWD

Joshi R, Marvin W.
PMID: 33788180
Eat Weight Disord. 2021 Mar 31; doi: 10.1007/s40519-021-01176-7. Epub 2021 Mar 31.

BACKGROUND: There is a paucity of literature around sedation and anesthesia in patients with severe anorexia nervosa. Chronically malnourished patients are known to have myopathy, neuropathy, and altered neurotransmitter signaling. Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist that...

Cite
Joshi R, Marvin W. Apnea with ketamine sedation in a patient with severe anorexia nervosa: A case report. Eat Weight Disord. 2021;doi: 10.1007/s40519-021-01176-7.
Joshi, R., & Marvin, W. (2021). Apnea with ketamine sedation in a patient with severe anorexia nervosa: A case report. Eating and weight disorders : EWD, . https://doi.org/10.1007/s40519-021-01176-7
Joshi, Reshma, and Marvin, Whitney. "Apnea with ketamine sedation in a patient with severe anorexia nervosa: A case report." Eating and weight disorders : EWD vol. (2021). doi: https://doi.org/10.1007/s40519-021-01176-7
Joshi R, Marvin W. Apnea with ketamine sedation in a patient with severe anorexia nervosa: A case report. Eat Weight Disord. 2021 Mar 31; doi: 10.1007/s40519-021-01176-7. Epub 2021 Mar 31. PMID: 33788180.
Copy Download .nbib Format: NLM
Obstructive sleep apnea as a risk factor for cardiovascular diseases.

Cardiology journal

Yilmaz F, Ozyildirim S, Talay F, Karaaslan K, Gunduz H.
PMID: 18651518
Cardiol J. 2007;14(6):534-7.

Obstructive sleep apnea (OSA) is a common medical condition that occurs in approximately 5% to 15% of the population. It is usually associated with an increased risk of cardiovascular disease. Diagnosis of OSA is based on polysomnography, and its...

Cite
Yilmaz F, Ozyildirim S, Talay F, et al. Obstructive sleep apnea as a risk factor for cardiovascular diseases. Cardiol J. 2007;14(6):534-7
Yilmaz, F., Ozyildirim, S., Talay, F., Karaaslan, K., & Gunduz, H. (2007). Obstructive sleep apnea as a risk factor for cardiovascular diseases. Cardiology journal, 14(6), 534-7.
Yilmaz, Fahrettin, et al. "Obstructive sleep apnea as a risk factor for cardiovascular diseases." Cardiology journal vol. 14,6 (2007): 534-7.
Yilmaz F, Ozyildirim S, Talay F, Karaaslan K, Gunduz H. Obstructive sleep apnea as a risk factor for cardiovascular diseases. Cardiol J. 2007;14(6):534-7. PMID: 18651518.
Copy Download .nbib Format: NLM
Causality assessment of cutaneous adverse drug reactions.

Annals of dermatology

Son YM, Lee JR, Roh JY.
PMID: 22148009
Ann Dermatol. 2011 Nov;23(4):432-8. doi: 10.5021/ad.2011.23.4.432. Epub 2011 Nov 03.

BACKGROUND: Cutaneous adverse drug reactions (ADRs) are the most common adverse reactions attributed to drugs. A systematic and effective approach to a patient with suspected drug eruption allows for prompt recognition, classification and treatment of cutaneous ADRs. A standardized...

Cite
Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Ann Dermatol. 2011;23(4):432-8doi: 10.5021/ad.2011.23.4.432.
Son, Y. M., Lee, J. R., & Roh, J. Y. (2011). Causality assessment of cutaneous adverse drug reactions. Annals of dermatology, 23(4), 432-8. https://doi.org/10.5021/ad.2011.23.4.432
Son, Young-Min, et al. "Causality assessment of cutaneous adverse drug reactions." Annals of dermatology vol. 23,4 (2011): 432-8. doi: https://doi.org/10.5021/ad.2011.23.4.432
Son YM, Lee JR, Roh JY. Causality assessment of cutaneous adverse drug reactions. Ann Dermatol. 2011 Nov;23(4):432-8. doi: 10.5021/ad.2011.23.4.432. Epub 2011 Nov 03. PMID: 22148009; PMCID: PMC3229935.
Copy Download .nbib Format: NLM
Sloughing esophagitis: a not so common entity.

International journal of biomedical science : IJBS

Akhondi H.
PMID: 25598761
Int J Biomed Sci. 2014 Dec;10(4):282-6.

BACKGROUND: Sloughing esophagitis, also known as esophagitis dissecans superficialis, is a very rare and underdiagnosed entity with unknown incidence rate. It can be associated with bullous dermatoses and medications such as central nervous system depressants and those causing esophageal...

Cite
Akhondi H. Sloughing esophagitis: a not so common entity. Int J Biomed Sci. 2014;10(4):282-6
Akhondi, H. (2014). Sloughing esophagitis: a not so common entity. International journal of biomedical science : IJBS, 10(4), 282-6.
Akhondi, Hossein. "Sloughing esophagitis: a not so common entity." International journal of biomedical science : IJBS vol. 10,4 (2014): 282-6.
Akhondi H. Sloughing esophagitis: a not so common entity. Int J Biomed Sci. 2014 Dec;10(4):282-6. PMID: 25598761; PMCID: PMC4289704.
Copy Download .nbib Format: NLM
Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study.

BMJ open

Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B.
PMID: 22492384
BMJ Open. 2012 Apr 05;2(2):e000614. doi: 10.1136/bmjopen-2011-000614. Print 2012.

OBJECTIVES: To investigate the prescription of potentially addictive drugs, including analgesics and central nervous system depressants, to women who had experienced intimate partner violence (IPV).DESIGN: Prospective population-based cohort study.SETTING: Information about IPV from the Oslo Health Study 2000/2001 was...

Cite
Stene LE, Dyb G, Tverdal A, et al. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012;2(2):e000614doi: 10.1136/bmjopen-2011-000614.
Stene, L. E., Dyb, G., Tverdal, A., Jacobsen, G. W., & Schei, B. (2012). Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ open, 2(2), e000614. https://doi.org/10.1136/bmjopen-2011-000614
Stene, Lise Eilin, et al. "Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study." BMJ open vol. 2,2 (2012): e000614. doi: https://doi.org/10.1136/bmjopen-2011-000614
Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Apr 05;2(2):e000614. doi: 10.1136/bmjopen-2011-000614. Print 2012. PMID: 22492384; PMCID: PMC3323816.
Copy Download .nbib Format: NLM
Patient considerations in the use of tapentadol for moderate to severe pain.

Drug, healthcare and patient safety

Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R.
PMID: 23861601
Drug Healthc Patient Saf. 2013 Jul 03;5:151-9. doi: 10.2147/DHPS.S28829. Print 2013.

Poorly controlled acute and chronic pain can increase morbidity, impair quality of life and prolong disability. Over 80 percent of post surgical patients report moderate to severe uncontrolled postoperative pain. Over-reliance on potent opioid agonists can lead to several...

Cite
Vadivelu N, Huang Y, Mirante B, et al. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf. 2013;5:151-9doi: 10.2147/DHPS.S28829.
Vadivelu, N., Huang, Y., Mirante, B., Jacoby, M., Braveman, F. R., Hines, R. L., & Sinatra, R. (2013). Patient considerations in the use of tapentadol for moderate to severe pain. Drug, healthcare and patient safety, 5151-9. https://doi.org/10.2147/DHPS.S28829
Vadivelu, Nalini, et al. "Patient considerations in the use of tapentadol for moderate to severe pain." Drug, healthcare and patient safety vol. 5 (2013): 151-9. doi: https://doi.org/10.2147/DHPS.S28829
Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman FR, Hines RL, Sinatra R. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf. 2013 Jul 03;5:151-9. doi: 10.2147/DHPS.S28829. Print 2013. PMID: 23861601; PMCID: PMC3704302.
Copy Download .nbib Format: NLM
Opioid and CNS-Depressant Medication Prescribing among Older Adults Enrolled in Medicare Advantage Versus Fee-for-Service Medicare.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

Lei L, Bynum JP, Maust DT.
PMID: 34565660
Am J Geriatr Psychiatry. 2021 Aug 28; doi: 10.1016/j.jagp.2021.08.010. Epub 2021 Aug 28.

OBJECTIVE: To examine whether prescription fills of opioids and central nervous system (CNS) depressants are lower in Medicare Advantage (MA) plans, which aim to provide more coordinated and integrated care, than fee-for-service (FFS) Medicare.METHODS: Data from the 2015 National...

Cite
Lei L, Bynum JP, Maust DT. Opioid and CNS-Depressant Medication Prescribing among Older Adults Enrolled in Medicare Advantage Versus Fee-for-Service Medicare. Am J Geriatr Psychiatry. 2021;doi: 10.1016/j.jagp.2021.08.010.
Lei, L., Bynum, J. P., & Maust, D. T. (2021). Opioid and CNS-Depressant Medication Prescribing among Older Adults Enrolled in Medicare Advantage Versus Fee-for-Service Medicare. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, . https://doi.org/10.1016/j.jagp.2021.08.010
Lei, Lianlian, et al. "Opioid and CNS-Depressant Medication Prescribing among Older Adults Enrolled in Medicare Advantage Versus Fee-for-Service Medicare." The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry vol. (2021). doi: https://doi.org/10.1016/j.jagp.2021.08.010
Lei L, Bynum JP, Maust DT. Opioid and CNS-Depressant Medication Prescribing among Older Adults Enrolled in Medicare Advantage Versus Fee-for-Service Medicare. Am J Geriatr Psychiatry. 2021 Aug 28; doi: 10.1016/j.jagp.2021.08.010. Epub 2021 Aug 28. PMID: 34565660.
Copy Download .nbib Format: NLM
Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis.

JAMA internal medicine

Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC.
PMID: 33104162
JAMA Intern Med. 2021 Jan 01;181(1):104-112. doi: 10.1001/jamainternmed.2020.5651.

IMPORTANCE: Fibromyalgia is a chronic condition that results in a significant burden to individuals and society.OBJECTIVE: To investigate the effectiveness of therapies for reducing pain and improving quality of life (QOL) in people with fibromyalgia.DATA SOURCES: Searches were performed...

Cite
Mascarenhas RO, Souza MB, Oliveira MX, et al. Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2021;181(1):104-112doi: 10.1001/jamainternmed.2020.5651.
Mascarenhas, R. O., Souza, M. B., Oliveira, M. X., Lacerda, A. C., Mendonça, V. A., Henschke, N., & Oliveira, V. C. (2021). Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA internal medicine, 181(1), 104-112. https://doi.org/10.1001/jamainternmed.2020.5651
Mascarenhas, Rodrigo Oliveira, et al. "Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis." JAMA internal medicine vol. 181,1 (2021): 104-112. doi: https://doi.org/10.1001/jamainternmed.2020.5651
Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC. Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2021 Jan 01;181(1):104-112. doi: 10.1001/jamainternmed.2020.5651. PMID: 33104162; PMCID: PMC7589080.
Copy Download .nbib Format: NLM
No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial.

The international journal of neuropsychopharmacology

Seifritz E, Möller HJ, Volz HP, Müller WE, Hopyan T, Wacker A, Schläfke S, Kasper S.
PMID: 33300578
Int J Neuropsychopharmacol. 2021 Mar 17;24(3):171-180. doi: 10.1093/ijnp/pyaa064.

BACKGROUND: Silexan is a lavender essential oil with established anxiolytic and calming efficacy. Here we asked whether there is a potential for abuse in human patients.METHODS: We carried out a phase I abuse liability single-center, double-blind, 5-way crossover study...

Cite
Seifritz E, Möller HJ, Volz HP, et al. No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. Int J Neuropsychopharmacol. 2021;24(3):171-180doi: 10.1093/ijnp/pyaa064.
Seifritz, E., Möller, H. J., Volz, H. P., Müller, W. E., Hopyan, T., Wacker, A., Schläfke, S., & Kasper, S. (2021). No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. The international journal of neuropsychopharmacology, 24(3), 171-180. https://doi.org/10.1093/ijnp/pyaa064
Seifritz, Erich, et al. "No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial." The international journal of neuropsychopharmacology vol. 24,3 (2021): 171-180. doi: https://doi.org/10.1093/ijnp/pyaa064
Seifritz E, Möller HJ, Volz HP, Müller WE, Hopyan T, Wacker A, Schläfke S, Kasper S. No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. Int J Neuropsychopharmacol. 2021 Mar 17;24(3):171-180. doi: 10.1093/ijnp/pyaa064. PMID: 33300578; PMCID: PMC7968617.
Copy Download .nbib Format: NLM
Gamma-Hydroxybutyrate (GHB) Withdrawal in a Patient with Polysubstance Use.

Journal of psychoactive drugs

Bernstein A.
PMID: 33357048
J Psychoactive Drugs. 2021 Sep-Oct;53(4):299-301. doi: 10.1080/02791072.2020.1865591. Epub 2020 Dec 24.

Gamma-hydroxybutyrate (GHB) and its various pro-drugs are GABA-B central nervous system depressants more commonly known as "G" and "liquid ecstasy" among those who consume. Due to the depressant quality of the substance and its convenience in online marketplaces, it...

Cite
Bernstein A. Gamma-Hydroxybutyrate (GHB) Withdrawal in a Patient with Polysubstance Use. J Psychoactive Drugs. 2020;53(4):299-301doi: 10.1080/02791072.2020.1865591.
Bernstein, A. (2021). Gamma-Hydroxybutyrate (GHB) Withdrawal in a Patient with Polysubstance Use. Journal of psychoactive drugs, 53(4), 299-301. https://doi.org/10.1080/02791072.2020.1865591
Bernstein, Adam. "Gamma-Hydroxybutyrate (GHB) Withdrawal in a Patient with Polysubstance Use." Journal of psychoactive drugs vol. 53,4 (2021): 299-301. doi: https://doi.org/10.1080/02791072.2020.1865591
Bernstein A. Gamma-Hydroxybutyrate (GHB) Withdrawal in a Patient with Polysubstance Use. J Psychoactive Drugs. 2021 Sep-Oct;53(4):299-301. doi: 10.1080/02791072.2020.1865591. Epub 2020 Dec 24. PMID: 33357048.
Copy Download .nbib Format: NLM
Aging out of the federal dependent coverage mandate and purchases of prescription drugs with high rates of misuse.

Economics and human biology

DiNardi M.
PMID: 34655854
Econ Hum Biol. 2021 Dec;43:101066. doi: 10.1016/j.ehb.2021.101066. Epub 2021 Oct 04.

Prescription central nervous system depressants, opioid pain relievers, and stimulants provide therapeutic value, but misuse for their recreational value is a growing problem in the United States. Because health insurance lowers the cost of purchasing prescription drugs, losing coverage...

Cite
DiNardi M. Aging out of the federal dependent coverage mandate and purchases of prescription drugs with high rates of misuse. Econ Hum Biol. 2021;43:101066doi: 10.1016/j.ehb.2021.101066.
DiNardi, M. (2021). Aging out of the federal dependent coverage mandate and purchases of prescription drugs with high rates of misuse. Economics and human biology, 43101066. https://doi.org/10.1016/j.ehb.2021.101066
DiNardi, Michael. "Aging out of the federal dependent coverage mandate and purchases of prescription drugs with high rates of misuse." Economics and human biology vol. 43 (2021): 101066. doi: https://doi.org/10.1016/j.ehb.2021.101066
DiNardi M. Aging out of the federal dependent coverage mandate and purchases of prescription drugs with high rates of misuse. Econ Hum Biol. 2021 Dec;43:101066. doi: 10.1016/j.ehb.2021.101066. Epub 2021 Oct 04. PMID: 34655854.
Copy Download .nbib Format: NLM
Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis.

JAMA internal medicine

Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC.
PMID: 33104162
JAMA Intern Med. 2021 Jan 01;181(1):104-112. doi: 10.1001/jamainternmed.2020.5651.

IMPORTANCE: Fibromyalgia is a chronic condition that results in a significant burden to individuals and society.OBJECTIVE: To investigate the effectiveness of therapies for reducing pain and improving quality of life (QOL) in people with fibromyalgia.DATA SOURCES: Searches were performed...

Cite
Mascarenhas RO, Souza MB, Oliveira MX, et al. Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2021;181(1):104-112doi: 10.1001/jamainternmed.2020.5651.
Mascarenhas, R. O., Souza, M. B., Oliveira, M. X., Lacerda, A. C., Mendonça, V. A., Henschke, N., & Oliveira, V. C. (2021). Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA internal medicine, 181(1), 104-112. https://doi.org/10.1001/jamainternmed.2020.5651
Mascarenhas, Rodrigo Oliveira, et al. "Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis." JAMA internal medicine vol. 181,1 (2021): 104-112. doi: https://doi.org/10.1001/jamainternmed.2020.5651
Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC. Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2021 Jan 01;181(1):104-112. doi: 10.1001/jamainternmed.2020.5651. PMID: 33104162; PMCID: PMC7589080.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 35 entries